MK-3475

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerGlioblastomaRadiation TherapyThymic Carcinoma

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Trodelvy

Gilead

Phase 3

112

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

13

HLX43

Shanghai Henlius Biotech

Phase 3

34

MK-3475

Pfizer

Phase 2

35

Remeron

OOrganon and Co

Preclinical

16

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—9

Treatment

GSK

Preclinical

110

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Pembrolizumab3 trials

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Completed·DDan Zandberg·Phase 2·NCT02289209·48 enrolled

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

Completed·AAlliance Foundation Trials, LLC.·Phase 2·NCT02591615·91 enrolled

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04098068·12 enrolled

Non-Small Cell Lung Cancer3 trials

MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients

Completed·IInstituto Nacional de Cancerologia de Mexico·Phase 2·NCT02574598·78 enrolled

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting·PProvidence Health & Services·Phase 1/2·NCT02422381·16 enrolled

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Completed·UUnknown Sponsor·Phase 1/2·NCT03003468·35 enrolled

Glioblastoma2 trials

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Unknown status·MMedical Research Council·Phase 1/2·NCT02430363·58 enrolled

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Active, not recruiting·—·Phase 1·NCT02852655·60 enrolled

Multiple Myeloma2 trials

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Terminated·AAshraf Badros·Phase 1/2·NCT02289222·48 enrolled

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02331368·32 enrolled

Renal Cell Carcinoma2 trials

Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

Completed·Novartis·Phase 1·NCT02014636·42 enrolled

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Completed·—·Phase 1/2·NCT02348008·61 enrolled

20 more indications

Melanoma2 trials

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Completed·HHassane M. Zarour, MD·Phase 1·NCT02112032·43 enrolled

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Completed·YYale University·Phase 2·NCT02085070·65 enrolled

Metastatic Melanoma1 trial

Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

Completed·YYale University·Phase 1/2·NCT02407171·61 enrolled

Endometrial Carcinoma1 trial

MK-3475 Immunotherapy in Endometrial Carcinoma

Completed·WWashington University School of Medicine·Phase 1·NCT02630823·10 enrolled

Patients With Solid Tumors1 trial

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Completed·Pfizer·Phase 1·NCT02179918·23 enrolled

Efficacy1 trial

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Completed·Incyte·Phase 1/2·NCT02178722·444 enrolled

Lung Cancer1 trial

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT02318771·41 enrolled

Breast Cancer1 trial

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Completed·EETOP IBCSG Partners Foundation·Phase 1/2·NCT02129556·58 enrolled

Radiation Therapy1 trial

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

Recruiting·—·Phase 2·NCT05879653·30 enrolled

T-cell non-Hodgkin lymphoma1 trial

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Terminated·FFox Chase Cancer Center·Phase 1/2·NCT02535247·17 enrolled

Malignant Glioma1 trial

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Completed·WWashington University School of Medicine·Phase 1/2·NCT02311582·55 enrolled

Renal Cell Cancer1 trial

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Completed·Pfizer·Phase 1·NCT02133742·52 enrolled

Chemotherapy1 trial

Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers

Terminated·UUniversity of Utah·Phase 1·NCT02268825·39 enrolled

Thymic Carcinoma1 trial

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

Recruiting·NNational Cancer Center, Japan·Phase 2·NCT05832827·35 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)

Completed·YYonsei University·Phase 2·NCT02844075·28 enrolled

Ovarian Squamous Cell Carcinoma1 trial

Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

Active, not recruiting·NNiigata University Medical & Dental Hospital·Phase 2·NCT05737199·21 enrolled

Nab-paclitaxel1 trial

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Terminated·NNisha Mohindra, MD·Phase 1/2·NCT02382406·46 enrolled

Tumors1 trial

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01876511·113 enrolled

Anti-PD-1 Antibody1 trial

Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 1·NCT02303366·15 enrolled

Colorectal Cancer1 trial

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02512172·27 enrolled

Head and Neck1 trial

Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma

Completed·WWashington University School of Medicine·Phase 2·NCT02296684·67 enrolled

Details

Drug Info

Related News